Journal
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume 14, Issue 10, Pages 1933-1948Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v14.i10.1933
Keywords
VCAN; Hepatocellular carcinoma; Hepatitis B virus; Immune checkpoints; Tumor microenvironment
Categories
Funding
- National Natural Science Foundation of China [31500650, 81902449]
- Key Research & Development Program-Social Development of Shaanxi Province [2020SF-063]
- Shaanxi Key Research and Development Plans [2021SF-227]
Ask authors/readers for more resources
The study found that VCAN is highly expressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis. In addition, VCAN is correlated with immune cell infiltration, immune checkpoint gene expression, and sensitivity to immune checkpoint inhibitor therapy.
BACKGROUND As a proteoglycan, VCAN exists in the tumor microenvironment and regulates tumor proliferation, invasion, and metastasis, but its role in hepatocellular carcinoma (HCC) has not yet been elucidated. AIM To investigate the expression and potential mechanism of action of VCAN in HCC. METHODS Based on The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset, we explored the correlation between VCAN expression and clinical features, and analyzed the prognosis of patients with high and low VCAN expression. The potential mechanism of action of VCAN was explored by Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes analysis, and gene set enrichment analysis. We also explored immune cell infiltration, immune checkpoint gene expression, and sensitivity of immune checkpoint [programmed cell death protein 1 (PD-1)/cytotoxic T lymphocyte antigen 4 (CTLA4)] inhibitor therapy in patients with different VCAN expression. VCAN mRNA expression and VCAN methylation in peripheral blood were tested in 100 hepatitis B virus (HBV)-related patients (50 HCC and 50 liver cirrhosis). RESULTS VCAN was highly expressed in HCC tissues, which was associated with a poor prognosis in HCC patients. No significant difference was found in VCAN mRNA expression in blood between patients with HBV-related cirrhosis and those with HCC, but there was a significant difference in VCAN methylation between the two groups. The correlation between VCAN and infiltrations of several different tumor immune cell types (including B cells, CD8(+) T cells, and eosinophils) was significantly different. VCAN was strongly related to immune checkpoint gene expression and tumor mutation burden, and could be a biomarker of sensitivity to immune checkpoint (PD1/CTLA4) inhibitors. In addition, VCAN mRNA expression was associated with hepatitis B e antigen, HBV DNA, white blood cells, platelets, cholesterol, and coagulation function. CONCLUSION High VCAN level could be a possible biomarker for poor prognosis of HCC, and its immunomodulatory mechanism in HCC warrants investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available